Spark's $4.8B Sale To Roche Is 'Unfair,' Investor Claims
A Spark Therapeutics Inc. investor has filed suit in Delaware federal court against the gene therapy company and its directors over its proposed $4.8 billion sale to F. Hoffmann-La Roche AG,...To view the full article, register now.
Already a subscriber? Click here to view full article